Try our Advanced Search for more refined results

FTC v. Boehringer Ingelheim Pharmace

  1. June 19, 2018

    DC Circ. Backs Boehringer In FTC Atty-Client Privilege Row

    The D.C. Circuit refused to overturn a ruling that communications subpoenaed from Boehringer Ingelheim Pharmaceuticals Inc. during a Federal Trade Commission pay-for-delay investigation are covered by attorney-client privilege, saying Tuesday one of their main purposes was to get legal advice.

  2. November 15, 2017

    DC Circ. Threads Needle On Docs Privilege In FTC Row

    A D.C. Circuit panel pressed lawyers for the Federal Trade Commission and Boehringer Ingelheim on Wednesday to spell out the fine line between attorney-client privilege and unprivileged business materials as the FTC investigates a possible pay-for-delay deal.

  3. August 22, 2017

    FTC, Boehringer Take Last Swipes In Docs Request Appeal

    The Federal Trade Commission and Boehringer Ingelheim each filed final briefs in the D.C. Circuit on Monday, with the sides sparring over a cache of documents from a 2008 Aggrenox patent dispute that the drugmaker alleges is protected by attorney-client privilege and the agency claims is not.

  4. June 05, 2017

    Corp. Attys Back Drug Co. In FTC Privilege Fight At DC Circ.

    Business and attorney advocacy groups urged the D.C. Circuit to deny the Federal Trade Commission's bid to force Boehringer Ingelheim to give up documents from a 2008 Aggrenox patent dispute, saying Friday that communications from the pharmaceutical company's in-house counsel must be protected.

  5. May 30, 2017

    FTC Would Shred Privilege In Aggrenox Suit, DC Circ. Told

    The Federal Trade Commission's bid to force Boehringer Ingelheim to hand over documents relating to a 2008 patent dispute settlement with Barr Pharmaceuticals over the drug Aggrenox would eviscerate the attorney-client privilege and undermine the work product doctrine, the drugmaker told the D.C. Circuit on Friday.

  6. April 12, 2017

    Boehringer Asks DC Circ. To Stay Aggrenox Doc Production

    Boehringer Ingelheim Pharmaceuticals Inc. has told the D.C. Circuit it would be irreparably harmed if it were forced to give the Federal Trade Commission documents on a 2008 patent dispute settlement over the drug Aggrenox and has asked the court to stay an order to produce the documents pending appeal.

  7. March 29, 2017

    FTC Tells DC Circ. To Undo Boehringer Doc Privilege Ruling

    The Federal Trade Commission urged the D.C. Circuit on Monday to reverse a lower court's ruling that some financial documents subpoenaed in its Aggrenox pay-for-delay case against Boehringer Ingelheim Pharmaceuticals are protected by attorney-client privilege, arguing that they concern business, not legal, matters.